Biogen Idec's hemophilia therapeutic area


	Press Releases
	July 12, 2010 BIOGEN IDEC AND SWEDISH ORPHAN BIOVITRUM PRESENT DATA ON LONG-LASTING HEMOPHILIA B THERAPY AT THE WORLD FEDERATION OF HEMOPHILIA CONGRESS July 9, 2010 BIOGEN IDEC AND SWEDISH ORPHAN BIOVITRUM ANNOUNCE DECISION TO ADVANCE LONG-LASTING HEMOPHILIA A THERAPY INTO A REGISTRATIONAL TRIAL February 18, 2010 BIOGEN IDEC AND SWEDISH ORPHAN BIOVITRUM UPDATE HEMOPHILIA PARTNERSHIP AGREEMENT January 25, 2010 BIOGEN IDEC AND SWEDISH ORPHAN BIOVITRUM ANNOUNCE FIRST PATIENT DOSED IN GLOBAL REGISTRATIONAL TRIAL OF LONG-ACTING HEMOPHILIA B THERAPY October 19, 2009 Biogen Idec and Biovitrum Announce Decision to Advance Long-Acting Hemophilia B Therapy into a Registrational Trial March 4, 2008 Biovitrum and Syntonix set to begin phase I/IIa clinical trial of long-acting recombinant Factor IXFc for the treatment of Hemophilia B January 4, 2007 BIOGEN IDEC TO ACQUIRE SYNTONIX January 23, 2006 BIOVITRUM AND SYNTONIX ENTER AGREEMENT FOR THE JOINT DEVELOPMENT AND COMMERCIALIZATION OF RECOMBINANT FACTOR IX FOR THE TREATMENT OF HEMOPHILIA Click here for other Biogen Idec press releases
	Home \| About \| Technology \| Hemophilia \| Clinical Programs \| Community \| Careers \| Contact Us Terms & Conditions of Use \| Note Regarding Forward-Looking Statements \| Privacy Policy \| Site Map © Biogen Idec - Biogen Idec is proud to be an Equal Opportunity Employer.